Sudeep Sahu scite author profile

Pharmaceutical grade 3 0 -deoxy-3 0 -[ 18 F]fluorothymidine [ 18 F]FLT was synthesized using 3-N-Boc-5 0 -O-dimethoxytrityl-3 0 -O-nosyl-thymidine (BOC-Nosyl) precursor, in the general purpose TRACERlab FX modules. Purification of [ 18 F]FLT, via solid phase extraction (SPE) after radiosynthesis, using a combination of different SPE cartridges, yielded satisfactory results, with radiochemical and chemical purity >99%. While the non-decay corrected radiochemical yield (RCY) with 20 mg (24 μmole) of BOC-Nosyl precursor was found to be 6.80 ± 0.16%, the decay corrected radiochemical yield (RCY) was 9.95 ± 0.24%. Residual acetone, acetonitrile, and ethanol levels were found to be 22.97

show abstract

Clinical Dose Preparation of [¹⁷⁷Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [¹⁷⁷Lu]LuCl₃ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Menon

Mitra²,

et al. 2022

Cancer Biotherapy and Radiopharmaceuticals

View full text Add to dashboard Cite

Comparative evaluation of 177Lu-DOTATATE and 90Y-DOTATATE in SSTR II overexpressing Xenograft models for treatment of variable volume neuroendocrine tumours

Tawate¹,

Sahu²,

Ak³

et al. 2022

Nuclear Medicine and Biology

View full text Add to dashboard Cite

In vitro study of 177Lu-DOTA-Trastuzumab and 177Lu-DOTA-Pertuzumab for evaluation of binding affinity towards human cell lines with differential expression of HER-2 receptor

Tawate¹,

Ak²,

Mitra³

et al. 2022

Nuclear Medicine and Biology

View full text Add to dashboard Cite

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Sudeep Sahu

Examining Absorbed Doses of Indigenously Developed ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy

Automated radiochemical synthesis of pharmaceutical grade [¹⁸F]FLT using 3‐N‐Boc‐5′‐O‐dimethoxytrityl‐3′‐O‐nosyl‐thymidine precursor and its Sep‐Pak® purification employing selective elution from reversed phase

Clinical Dose Preparation of [¹⁷⁷Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [¹⁷⁷Lu]LuCl₃ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Comparative evaluation of 177Lu-DOTATATE and 90Y-DOTATATE in SSTR II overexpressing Xenograft models for treatment of variable volume neuroendocrine tumours

In vitro study of 177Lu-DOTA-Trastuzumab and 177Lu-DOTA-Pertuzumab for evaluation of binding affinity towards human cell lines with differential expression of HER-2 receptor

Contact Info

Product

Resources

About

Sudeep Sahu

Examining Absorbed Doses of Indigenously Developed 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy

Automated radiochemical synthesis of pharmaceutical grade [18F]FLT using 3‐N‐Boc‐5′‐O‐dimethoxytrityl‐3′‐O‐nosyl‐thymidine precursor and its Sep‐Pak® purification employing selective elution from reversed phase

Clinical Dose Preparation of [177Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [177Lu]LuCl3 for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression

Comparative evaluation of 177Lu-DOTATATE and 90Y-DOTATATE in SSTR II overexpressing Xenograft models for treatment of variable volume neuroendocrine tumours

In vitro study of 177Lu-DOTA-Trastuzumab and 177Lu-DOTA-Pertuzumab for evaluation of binding affinity towards human cell lines with differential expression of HER-2 receptor

Contact Info

Product

Resources

About

Examining Absorbed Doses of Indigenously Developed ¹⁷⁷Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer Patients at Baseline and During Course of Peptide Receptor Radioligand Therapy

Automated radiochemical synthesis of pharmaceutical grade [¹⁸F]FLT using 3‐N‐Boc‐5′‐O‐dimethoxytrityl‐3′‐O‐nosyl‐thymidine precursor and its Sep‐Pak® purification employing selective elution from reversed phase

Clinical Dose Preparation of [¹⁷⁷Lu]Lu-DOTA-Pertuzumab Using Medium Specific Activity [¹⁷⁷Lu]LuCl₃ for Radioimmunotherapy of Breast and Epithelial Ovarian Cancers, with HER2 Receptor Overexpression